Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 414.80% from the stock’s previous close.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Wedbush boosted their price objective on shares of Kura Oncology from $34.00 to $36.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $7.77 on Thursday. The stock has a market capitalization of $604.23 million, a P/E ratio of -3.29 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business has a 50-day moving average of $8.19 and a two-hundred day moving average of $13.92. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, equities research analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity

In other news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,729 shares of company stock worth $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of KURA. Virtus ETF Advisers LLC increased its holdings in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC bought a new stake in shares of Kura Oncology during the fourth quarter worth $87,000. E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the fourth quarter valued at $90,000. Corton Capital Inc. bought a new position in shares of Kura Oncology in the fourth quarter valued at about $99,000. Finally, Optimize Financial Inc bought a new position in shares of Kura Oncology in the fourth quarter valued at about $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.